SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center

SOPHiA GENETICS  announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint venture between the two institutions. The joint venture aims to build upon the strength of MSK innovation in clinical diagnostics and SOPHiA GENETICS's Ai platform to potentially discover, develop, and deploy a new generation of precision oncology to patients around the world.

The MOU envisions a precision medicine hub that would combine MSK's clinical data and expertise with SOPHiA GENETICS's Ai platform to unlock a new approach to multimodal precision oncology.

SOPHiA GENETICS's announcement of this Memorandum of Understanding comes at a pivotal moment in oncology, as interest in Ai-enabled precision medicine continues to grow. New targeted cancer therapies are pushing molecular diagnostics earlier in the treatment pathway, creating demand for new diagnostic capabilities and scalable testing platforms. At the same time, Ai is emerging as a critical tool for clinical decision-making, making the combination of clinical data and Ai infrastructure one of the field's most strategic capabilities.

Ross Muken, President, SOPHiA GENETICS, said: "Our work with MSK has always been about extending the reach of MSK's clinical intelligence, and this joint venture is the most ambitious expression of that mission yet. Over the past several years, we've built SOPHiA DDM™ into a foundational Ai and analytics layer for precision medicine, helping institutions across the world unlock the value of their clinical data. By combining MSK's clinical leadership and deep clinical data with SOPHiA GENETICS's Ai platform and global infrastructure, the precision medicine hub that we are discussing will help move precision oncology into the multimodal era and bring the benefits of MSK's precision oncology to patients regardless of where they're treated."

Michael G. Frank, Director of Digital Health Business Development at MSK, said: "This collaboration represents the future of applied precision oncology – where clinical expertise meets cutting-edge Ai and robotics with the potential to transform cancer care at scale. By combining MSK's deep clinical assets with SOPHiA GENETICS's powerful digital platform, we're seeking to create a new paradigm to deliver personalized insights to patients."